Oxford BioMedica plc · LSE:OXB
Oxford BioMedica — Merger or Acquisition (February 2018)
17 slides from Oxford BioMedica's merger presentation, Feb 15, 2018
Slide 1: The LentiVector Platform Company
The LentiVector® Platform Company A leader in gene and cell therapy Oxford BioMedica and Bioverativ Collaboration and Licence Agreement 15 February 2018
Slide 2: Forward-looking statements
Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed 2 Cohort
Slide 3: World's leading gene and cell therapy company
World’s leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Mean 29%
Slide 4: Strategy: Leveraging our delivery platform
Strategy: Leveraging our delivery platform LentiVector® Platform IP – patents and know-how | Facilities | Expertise | Quality systems Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max
Slide 5: Collaboration & Licence Agreement
Collaboration & Licence Agreement © Oxford BioMedica 2015, all rights reserved 5
Slide 6: Collaboration & Licence Agreement with Bioverativ
Collaboration & Licence Agreement with Collaboration overview Key Terms Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1,• n=3Development 1x of in vivo gene therapy for: Mean 27%• Original $5 million Mean 30%on closing Mean 29% Mean 20% Max. up to 30% Ma
Slide 7: Bioverativ
Bioverativ • Bioverativ was an independent biopharmaceutical company spun out of Biogen’s haemophilia business in 2017 but is now subject to an acquisition by Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Sanofi 1, n=3 1x Original Mean 27% Mean 30% Mean
Slide 8: Haemophilia Market
Haemophilia Market • Haemophilia is an x-linked hereditary bleeding disorder characterised by impaired blood coagulation as result of deficiencies in the production or Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3function of 1x coagulation Factor
Slide 9: How gene therapy addresses haemophilia
How gene therapy addresses haemophilia In vivo gene therapy to produce FVIII and FIX to treat haemophilia A and B respectively Cohort2 Dose Administration 3 months (UPDRS) 1. DNA 6 months encoding (UPDRS) either FVIII 1 year (UPDRS) or(UPDRS) 2 years FIX 1, n=3 1x Original Mean 27% Mean is30%produce
Slide 10: Oxford BioMedica's Latest Product Portfolio
Oxford BioMedica’s Latest Product Portfolio © Oxford BioMedica 2015, all rights reserved 10
Slide 11: Product pipeline
Product pipeline Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval OXB Proprietary Products OXB-102 Parkinson’s disease Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) OXB-202 Corneal graft rejection To be spun out 1, n=3 1x O
Slide 12: Extensive lentiviral vector clinical/pre-clinical trial activity
Extensive lentiviral vector clinical/pre-clinical trial activity New York Times, Gina Kolata Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year(27 (UPDRS) 2 years (UPDRS) November 2017) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% "Few Max. u
Slide 13: Summary
Summary © Oxford BioMedica 2015, all rights reserved 13
Slide 14: Summary: World's leading gene and cell therapy company
Summary: World’s leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34%
Slide 15: Expected upcoming news flow
Expected upcoming news flow Partners’ programmes progress Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 2nd CAR-T Royalties Expected approval for Expected EMA approval for 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% programme to commence from
Slide 16: Vision of Oxford BioMedica – by end of 2018
Vision of Oxford BioMedica – by end of 2018 Core LentiVector® Product pipeline Bioprocessing platform R&D Bioprocessing Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Facilities operating at, 1, n=3 product candidates New 1x OXB priority Original product
Slide 17: Contact Us
Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Stuart Paynter, CFO Tel: +44 (0) 1865 783 000 [email protected] www.oxfordbiomedica.co.uk
Oxford BioMedica — Merger or Acquisition (February 2018) on 6ix